Medical Devices & Consumables
Global Gene Therapy On Cardiovascular Disease Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
- Aug 04, 25
- ID: 424815
- Pages: 105
- Figures: 103
- Views: 1
The global Gene Therapy On Cardiovascular Disease market size was US$ 322 million in 2024 and is forecast to a readjusted size of US$ 28430 million by 2031 with a CAGR of 91.0% during the forecast period 2025-2031.
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery. Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.
Market Driver: The increasing prevalence of cardiovascular diseases (CVDs) worldwide is a major driver for the gene therapy market in this area. As traditional treatments, such as surgery, medications, and lifestyle changes, sometimes fail to offer long-term solutions, gene therapy presents a promising alternative. By targeting the root causes of CVDs at the genetic level, gene therapy offers the potential for more effective and durable treatments. Advancements in gene editing technologies, such as CRISPR, have further accelerated the development of gene therapies for cardiovascular diseases, allowing for precise modification of genes that regulate heart function, blood vessel health, and inflammation. This technological progress, combined with the growing demand for personalized and innovative treatments, is driving the market forward.Market Challenge: Despite its potential, the gene therapy market for cardiovascular diseases faces several challenges, including high development costs and the complexity of clinical trials. Developing safe and effective gene therapies requires significant investment in research and long-term testing, which can delay the availability of these therapies to patients. Additionally, regulatory approval for gene therapies can be slow and uncertain, creating barriers to rapid commercialization. Moreover, there are concerns regarding the long-term safety and potential unintended genetic consequences of modifying human DNA, which may limit widespread adoption. The complexity of delivering gene therapies to the cardiovascular system, such as targeting specific cells or tissues without causing adverse effects, remains a significant technical challenge.
Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%.
The global Gene Therapy On Cardiovascular Disease market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Renovacor
Gene Biotherapeutics
AskBio
Human Stem Cells Institute
Novartis
Biogen
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
By Type: (Dominant Segment vs High-Margin Innovation)
Viral Gene Therapy
Non-Viral Gene Therapy
By Application: (Core Demand Driver vs Emerging Opportunity)
Heart Disease
Vascular Disease
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Renovacor in Europe)
- Emerging Product Trends: Viral Gene Therapy adoption vs. Non-Viral Gene Therapy premiumization
- Demand-Side Dynamics: Heart Disease growth in China vs. Vascular Disease potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
(Additional regions can be customized based on client needs.)
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Gene Therapy On Cardiovascular Disease market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Non-Viral Gene Therapy in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Vascular Disease in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Gene Therapy On Cardiovascular Disease value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery. Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.
Market Driver: The increasing prevalence of cardiovascular diseases (CVDs) worldwide is a major driver for the gene therapy market in this area. As traditional treatments, such as surgery, medications, and lifestyle changes, sometimes fail to offer long-term solutions, gene therapy presents a promising alternative. By targeting the root causes of CVDs at the genetic level, gene therapy offers the potential for more effective and durable treatments. Advancements in gene editing technologies, such as CRISPR, have further accelerated the development of gene therapies for cardiovascular diseases, allowing for precise modification of genes that regulate heart function, blood vessel health, and inflammation. This technological progress, combined with the growing demand for personalized and innovative treatments, is driving the market forward.Market Challenge: Despite its potential, the gene therapy market for cardiovascular diseases faces several challenges, including high development costs and the complexity of clinical trials. Developing safe and effective gene therapies requires significant investment in research and long-term testing, which can delay the availability of these therapies to patients. Additionally, regulatory approval for gene therapies can be slow and uncertain, creating barriers to rapid commercialization. Moreover, there are concerns regarding the long-term safety and potential unintended genetic consequences of modifying human DNA, which may limit widespread adoption. The complexity of delivering gene therapies to the cardiovascular system, such as targeting specific cells or tissues without causing adverse effects, remains a significant technical challenge.
Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%.
The global Gene Therapy On Cardiovascular Disease market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Renovacor
Gene Biotherapeutics
AskBio
Human Stem Cells Institute
Novartis
Biogen
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
By Type: (Dominant Segment vs High-Margin Innovation)
Viral Gene Therapy
Non-Viral Gene Therapy
By Application: (Core Demand Driver vs Emerging Opportunity)
Heart Disease
Vascular Disease
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Renovacor in Europe)
- Emerging Product Trends: Viral Gene Therapy adoption vs. Non-Viral Gene Therapy premiumization
- Demand-Side Dynamics: Heart Disease growth in China vs. Vascular Disease potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
(Additional regions can be customized based on client needs.)
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Gene Therapy On Cardiovascular Disease market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Non-Viral Gene Therapy in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Vascular Disease in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Gene Therapy On Cardiovascular Disease value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Viral Gene Therapy
1.2.3 Non-Viral Gene Therapy
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Heart Disease
1.3.3 Vascular Disease
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy On Cardiovascular Disease Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Region (2020-2025)
2.4 Global Gene Therapy On Cardiovascular Disease Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Gene Therapy On Cardiovascular Disease Market Size and Prospective (2020-2031)
2.5.2 Europe Gene Therapy On Cardiovascular Disease Market Size and Prospective (2020-2031)
2.5.3 China Gene Therapy On Cardiovascular Disease Market Size and Prospective (2020-2031)
2.5.4 Japan Gene Therapy On Cardiovascular Disease Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Gene Therapy On Cardiovascular Disease Historic Market Size by Type (2020-2025)
3.2 Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Type (2026-2031)
3.3 Different Types Gene Therapy On Cardiovascular Disease Representative Players
4 Breakdown Data by Application
4.1 Global Gene Therapy On Cardiovascular Disease Historic Market Size by Application (2020-2025)
4.2 Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Gene Therapy On Cardiovascular Disease Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Gene Therapy On Cardiovascular Disease Players by Revenue (2020-2025)
5.1.2 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Gene Therapy On Cardiovascular Disease Revenue
5.4 Global Gene Therapy On Cardiovascular Disease Market Concentration Analysis
5.4.1 Global Gene Therapy On Cardiovascular Disease Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Gene Therapy On Cardiovascular Disease Revenue in 2024
5.5 Global Key Players of Gene Therapy On Cardiovascular Disease Head office and Area Served
5.6 Global Key Players of Gene Therapy On Cardiovascular Disease, Product and Application
5.7 Global Key Players of Gene Therapy On Cardiovascular Disease, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025)
6.1.2.2 North America Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025)
6.1.3.2 North America Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025)
6.2.2.2 Europe Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025)
6.2.3.2 Europe Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments and Downstream
6.3.1 China Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025)
6.3.2 China Market Size by Type
6.3.2.1 China Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025)
6.3.2.2 China Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
6.3.3 China Market Size by Application
6.3.3.1 China Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025)
6.3.3.2 China Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
6.3.4 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments and Downstream
6.4.1 Japan Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025)
6.4.2.2 Japan Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025)
6.4.3.2 Japan Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
6.4.4 Japan Market Trend and Opportunities
7 Key Players Profiles
7.1 Renovacor
7.1.1 Renovacor Company Details
7.1.2 Renovacor Business Overview
7.1.3 Renovacor Gene Therapy On Cardiovascular Disease Introduction
7.1.4 Renovacor Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.1.5 Renovacor Recent Development
7.2 Gene Biotherapeutics
7.2.1 Gene Biotherapeutics Company Details
7.2.2 Gene Biotherapeutics Business Overview
7.2.3 Gene Biotherapeutics Gene Therapy On Cardiovascular Disease Introduction
7.2.4 Gene Biotherapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.2.5 Gene Biotherapeutics Recent Development
7.3 AskBio
7.3.1 AskBio Company Details
7.3.2 AskBio Business Overview
7.3.3 AskBio Gene Therapy On Cardiovascular Disease Introduction
7.3.4 AskBio Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.3.5 AskBio Recent Development
7.4 Human Stem Cells Institute
7.4.1 Human Stem Cells Institute Company Details
7.4.2 Human Stem Cells Institute Business Overview
7.4.3 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Introduction
7.4.4 Human Stem Cells Institute Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.4.5 Human Stem Cells Institute Recent Development
7.5 Novartis
7.5.1 Novartis Company Details
7.5.2 Novartis Business Overview
7.5.3 Novartis Gene Therapy On Cardiovascular Disease Introduction
7.5.4 Novartis Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.5.5 Novartis Recent Development
7.6 Biogen
7.6.1 Biogen Company Details
7.6.2 Biogen Business Overview
7.6.3 Biogen Gene Therapy On Cardiovascular Disease Introduction
7.6.4 Biogen Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.6.5 Biogen Recent Development
7.7 Gilead Sciences
7.7.1 Gilead Sciences Company Details
7.7.2 Gilead Sciences Business Overview
7.7.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Introduction
7.7.4 Gilead Sciences Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.7.5 Gilead Sciences Recent Development
7.8 Sarepta Therapeutics
7.8.1 Sarepta Therapeutics Company Details
7.8.2 Sarepta Therapeutics Business Overview
7.8.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Introduction
7.8.4 Sarepta Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.8.5 Sarepta Therapeutics Recent Development
7.9 Alnylam Pharmaceuticals
7.9.1 Alnylam Pharmaceuticals Company Details
7.9.2 Alnylam Pharmaceuticals Business Overview
7.9.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Introduction
7.9.4 Alnylam Pharmaceuticals Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.9.5 Alnylam Pharmaceuticals Recent Development
7.10 Amgen
7.10.1 Amgen Company Details
7.10.2 Amgen Business Overview
7.10.3 Amgen Gene Therapy On Cardiovascular Disease Introduction
7.10.4 Amgen Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.10.5 Amgen Recent Development
7.11 Spark Therapeutics
7.11.1 Spark Therapeutics Company Details
7.11.2 Spark Therapeutics Business Overview
7.11.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Introduction
7.11.4 Spark Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.11.5 Spark Therapeutics Recent Development
7.12 Akcea Therapeutics
7.12.1 Akcea Therapeutics Company Details
7.12.2 Akcea Therapeutics Business Overview
7.12.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Introduction
7.12.4 Akcea Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.12.5 Akcea Therapeutics Recent Development
7.13 Sunway Biotech
7.13.1 Sunway Biotech Company Details
7.13.2 Sunway Biotech Business Overview
7.13.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Introduction
7.13.4 Sunway Biotech Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.13.5 Sunway Biotech Recent Development
7.14 SIBIONO
7.14.1 SIBIONO Company Details
7.14.2 SIBIONO Business Overview
7.14.3 SIBIONO Gene Therapy On Cardiovascular Disease Introduction
7.14.4 SIBIONO Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.14.5 SIBIONO Recent Development
7.15 AnGes
7.15.1 AnGes Company Details
7.15.2 AnGes Business Overview
7.15.3 AnGes Gene Therapy On Cardiovascular Disease Introduction
7.15.4 AnGes Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.15.5 AnGes Recent Development
7.16 Orchard Therapeutics
7.16.1 Orchard Therapeutics Company Details
7.16.2 Orchard Therapeutics Business Overview
7.16.3 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Introduction
7.16.4 Orchard Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.16.5 Orchard Therapeutics Recent Development
8 Gene Therapy On Cardiovascular Disease Market Dynamics
8.1 Gene Therapy On Cardiovascular Disease Industry Trends
8.2 Gene Therapy On Cardiovascular Disease Market Drivers
8.3 Gene Therapy On Cardiovascular Disease Market Challenges
8.4 Gene Therapy On Cardiovascular Disease Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Viral Gene Therapy
1.2.3 Non-Viral Gene Therapy
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Heart Disease
1.3.3 Vascular Disease
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy On Cardiovascular Disease Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Region (2020-2025)
2.4 Global Gene Therapy On Cardiovascular Disease Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Gene Therapy On Cardiovascular Disease Market Size and Prospective (2020-2031)
2.5.2 Europe Gene Therapy On Cardiovascular Disease Market Size and Prospective (2020-2031)
2.5.3 China Gene Therapy On Cardiovascular Disease Market Size and Prospective (2020-2031)
2.5.4 Japan Gene Therapy On Cardiovascular Disease Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Gene Therapy On Cardiovascular Disease Historic Market Size by Type (2020-2025)
3.2 Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Type (2026-2031)
3.3 Different Types Gene Therapy On Cardiovascular Disease Representative Players
4 Breakdown Data by Application
4.1 Global Gene Therapy On Cardiovascular Disease Historic Market Size by Application (2020-2025)
4.2 Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Gene Therapy On Cardiovascular Disease Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Gene Therapy On Cardiovascular Disease Players by Revenue (2020-2025)
5.1.2 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Gene Therapy On Cardiovascular Disease Revenue
5.4 Global Gene Therapy On Cardiovascular Disease Market Concentration Analysis
5.4.1 Global Gene Therapy On Cardiovascular Disease Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Gene Therapy On Cardiovascular Disease Revenue in 2024
5.5 Global Key Players of Gene Therapy On Cardiovascular Disease Head office and Area Served
5.6 Global Key Players of Gene Therapy On Cardiovascular Disease, Product and Application
5.7 Global Key Players of Gene Therapy On Cardiovascular Disease, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025)
6.1.2.2 North America Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025)
6.1.3.2 North America Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025)
6.2.2.2 Europe Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025)
6.2.3.2 Europe Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments and Downstream
6.3.1 China Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025)
6.3.2 China Market Size by Type
6.3.2.1 China Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025)
6.3.2.2 China Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
6.3.3 China Market Size by Application
6.3.3.1 China Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025)
6.3.3.2 China Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
6.3.4 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments and Downstream
6.4.1 Japan Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025)
6.4.2.2 Japan Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025)
6.4.3.2 Japan Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
6.4.4 Japan Market Trend and Opportunities
7 Key Players Profiles
7.1 Renovacor
7.1.1 Renovacor Company Details
7.1.2 Renovacor Business Overview
7.1.3 Renovacor Gene Therapy On Cardiovascular Disease Introduction
7.1.4 Renovacor Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.1.5 Renovacor Recent Development
7.2 Gene Biotherapeutics
7.2.1 Gene Biotherapeutics Company Details
7.2.2 Gene Biotherapeutics Business Overview
7.2.3 Gene Biotherapeutics Gene Therapy On Cardiovascular Disease Introduction
7.2.4 Gene Biotherapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.2.5 Gene Biotherapeutics Recent Development
7.3 AskBio
7.3.1 AskBio Company Details
7.3.2 AskBio Business Overview
7.3.3 AskBio Gene Therapy On Cardiovascular Disease Introduction
7.3.4 AskBio Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.3.5 AskBio Recent Development
7.4 Human Stem Cells Institute
7.4.1 Human Stem Cells Institute Company Details
7.4.2 Human Stem Cells Institute Business Overview
7.4.3 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Introduction
7.4.4 Human Stem Cells Institute Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.4.5 Human Stem Cells Institute Recent Development
7.5 Novartis
7.5.1 Novartis Company Details
7.5.2 Novartis Business Overview
7.5.3 Novartis Gene Therapy On Cardiovascular Disease Introduction
7.5.4 Novartis Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.5.5 Novartis Recent Development
7.6 Biogen
7.6.1 Biogen Company Details
7.6.2 Biogen Business Overview
7.6.3 Biogen Gene Therapy On Cardiovascular Disease Introduction
7.6.4 Biogen Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.6.5 Biogen Recent Development
7.7 Gilead Sciences
7.7.1 Gilead Sciences Company Details
7.7.2 Gilead Sciences Business Overview
7.7.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Introduction
7.7.4 Gilead Sciences Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.7.5 Gilead Sciences Recent Development
7.8 Sarepta Therapeutics
7.8.1 Sarepta Therapeutics Company Details
7.8.2 Sarepta Therapeutics Business Overview
7.8.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Introduction
7.8.4 Sarepta Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.8.5 Sarepta Therapeutics Recent Development
7.9 Alnylam Pharmaceuticals
7.9.1 Alnylam Pharmaceuticals Company Details
7.9.2 Alnylam Pharmaceuticals Business Overview
7.9.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Introduction
7.9.4 Alnylam Pharmaceuticals Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.9.5 Alnylam Pharmaceuticals Recent Development
7.10 Amgen
7.10.1 Amgen Company Details
7.10.2 Amgen Business Overview
7.10.3 Amgen Gene Therapy On Cardiovascular Disease Introduction
7.10.4 Amgen Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.10.5 Amgen Recent Development
7.11 Spark Therapeutics
7.11.1 Spark Therapeutics Company Details
7.11.2 Spark Therapeutics Business Overview
7.11.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Introduction
7.11.4 Spark Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.11.5 Spark Therapeutics Recent Development
7.12 Akcea Therapeutics
7.12.1 Akcea Therapeutics Company Details
7.12.2 Akcea Therapeutics Business Overview
7.12.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Introduction
7.12.4 Akcea Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.12.5 Akcea Therapeutics Recent Development
7.13 Sunway Biotech
7.13.1 Sunway Biotech Company Details
7.13.2 Sunway Biotech Business Overview
7.13.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Introduction
7.13.4 Sunway Biotech Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.13.5 Sunway Biotech Recent Development
7.14 SIBIONO
7.14.1 SIBIONO Company Details
7.14.2 SIBIONO Business Overview
7.14.3 SIBIONO Gene Therapy On Cardiovascular Disease Introduction
7.14.4 SIBIONO Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.14.5 SIBIONO Recent Development
7.15 AnGes
7.15.1 AnGes Company Details
7.15.2 AnGes Business Overview
7.15.3 AnGes Gene Therapy On Cardiovascular Disease Introduction
7.15.4 AnGes Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.15.5 AnGes Recent Development
7.16 Orchard Therapeutics
7.16.1 Orchard Therapeutics Company Details
7.16.2 Orchard Therapeutics Business Overview
7.16.3 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Introduction
7.16.4 Orchard Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
7.16.5 Orchard Therapeutics Recent Development
8 Gene Therapy On Cardiovascular Disease Market Dynamics
8.1 Gene Therapy On Cardiovascular Disease Industry Trends
8.2 Gene Therapy On Cardiovascular Disease Market Drivers
8.3 Gene Therapy On Cardiovascular Disease Market Challenges
8.4 Gene Therapy On Cardiovascular Disease Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Gene Therapy On Cardiovascular Disease Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Gene Therapy On Cardiovascular Disease Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Gene Therapy On Cardiovascular Disease Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Gene Therapy On Cardiovascular Disease Revenue Share by Region (2020-2025)
Table 6. Global Gene Therapy On Cardiovascular Disease Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Gene Therapy On Cardiovascular Disease Revenue Share Forecast by Region (2026-2031)
Table 8. Global Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2020-2025)
Table 10. Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2020-2025)
Table 15. Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Gene Therapy On Cardiovascular Disease Application
Table 18. Global Gene Therapy On Cardiovascular Disease Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Gene Therapy On Cardiovascular Disease Market Share by Players (2020-2025)
Table 20. Global Top Gene Therapy On Cardiovascular Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy On Cardiovascular Disease as of 2024)
Table 21. Ranking of Global Top Gene Therapy On Cardiovascular Disease Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Gene Therapy On Cardiovascular Disease Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Gene Therapy On Cardiovascular Disease, Headquarters and Area Served
Table 24. Global Key Players of Gene Therapy On Cardiovascular Disease, Product and Application
Table 25. Global Key Players of Gene Therapy On Cardiovascular Disease, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Gene Therapy On Cardiovascular Disease Revenue Market Share by Company (2020-2025)
Table 29. North America Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Gene Therapy On Cardiovascular Disease Revenue Market Share by Company (2020-2025)
Table 33. Europe Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025) & (US$ Million)
Table 35. China Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025) & (US$ Million)
Table 36. China Gene Therapy On Cardiovascular Disease Revenue Market Share by Company (2020-2025)
Table 37. China Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025) & (US$ Million)
Table 38. China Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025) & (US$ Million)
Table 39. Japan Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025) & (US$ Million)
Table 40. Japan Gene Therapy On Cardiovascular Disease Revenue Market Share by Company (2020-2025)
Table 41. Japan Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025) & (US$ Million)
Table 42. Japan Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025) & (US$ Million)
Table 43. Renovacor Company Details
Table 44. Renovacor Business Overview
Table 45. Renovacor Gene Therapy On Cardiovascular Disease Product
Table 46. Renovacor Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 47. Renovacor Recent Development
Table 48. Gene Biotherapeutics Company Details
Table 49. Gene Biotherapeutics Business Overview
Table 50. Gene Biotherapeutics Gene Therapy On Cardiovascular Disease Product
Table 51. Gene Biotherapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 52. Gene Biotherapeutics Recent Development
Table 53. AskBio Company Details
Table 54. AskBio Business Overview
Table 55. AskBio Gene Therapy On Cardiovascular Disease Product
Table 56. AskBio Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 57. AskBio Recent Development
Table 58. Human Stem Cells Institute Company Details
Table 59. Human Stem Cells Institute Business Overview
Table 60. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product
Table 61. Human Stem Cells Institute Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 62. Human Stem Cells Institute Recent Development
Table 63. Novartis Company Details
Table 64. Novartis Business Overview
Table 65. Novartis Gene Therapy On Cardiovascular Disease Product
Table 66. Novartis Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 67. Novartis Recent Development
Table 68. Biogen Company Details
Table 69. Biogen Business Overview
Table 70. Biogen Gene Therapy On Cardiovascular Disease Product
Table 71. Biogen Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 72. Biogen Recent Development
Table 73. Gilead Sciences Company Details
Table 74. Gilead Sciences Business Overview
Table 75. Gilead Sciences Gene Therapy On Cardiovascular Disease Product
Table 76. Gilead Sciences Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 77. Gilead Sciences Recent Development
Table 78. Sarepta Therapeutics Company Details
Table 79. Sarepta Therapeutics Business Overview
Table 80. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product
Table 81. Sarepta Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 82. Sarepta Therapeutics Recent Development
Table 83. Alnylam Pharmaceuticals Company Details
Table 84. Alnylam Pharmaceuticals Business Overview
Table 85. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product
Table 86. Alnylam Pharmaceuticals Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 87. Alnylam Pharmaceuticals Recent Development
Table 88. Amgen Company Details
Table 89. Amgen Business Overview
Table 90. Amgen Gene Therapy On Cardiovascular Disease Product
Table 91. Amgen Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 92. Amgen Recent Development
Table 93. Spark Therapeutics Company Details
Table 94. Spark Therapeutics Business Overview
Table 95. Spark Therapeutics Gene Therapy On Cardiovascular Disease Product
Table 96. Spark Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 97. Spark Therapeutics Recent Development
Table 98. Akcea Therapeutics Company Details
Table 99. Akcea Therapeutics Business Overview
Table 100. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product
Table 101. Akcea Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 102. Akcea Therapeutics Recent Development
Table 103. Sunway Biotech Company Details
Table 104. Sunway Biotech Business Overview
Table 105. Sunway Biotech Gene Therapy On Cardiovascular Disease Product
Table 106. Sunway Biotech Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 107. Sunway Biotech Recent Development
Table 108. SIBIONO Company Details
Table 109. SIBIONO Business Overview
Table 110. SIBIONO Gene Therapy On Cardiovascular Disease Product
Table 111. SIBIONO Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 112. SIBIONO Recent Development
Table 113. AnGes Company Details
Table 114. AnGes Business Overview
Table 115. AnGes Gene Therapy On Cardiovascular Disease Product
Table 116. AnGes Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 117. AnGes Recent Development
Table 118. Orchard Therapeutics Company Details
Table 119. Orchard Therapeutics Business Overview
Table 120. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product
Table 121. Orchard Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 122. Orchard Therapeutics Recent Development
Table 123. Gene Therapy On Cardiovascular Disease Market Trends
Table 124. Gene Therapy On Cardiovascular Disease Market Drivers
Table 125. Gene Therapy On Cardiovascular Disease Market Challenges
Table 126. Gene Therapy On Cardiovascular Disease Market Restraints
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of Figures
Figure 1. Gene Therapy On Cardiovascular Disease Product Picture
Figure 2. Global Gene Therapy On Cardiovascular Disease Market Share by Type: 2024 VS 2031
Figure 3. Viral Gene Therapy Features
Figure 4. Non-Viral Gene Therapy Features
Figure 5. Global Gene Therapy On Cardiovascular Disease Market Share by Application: 2024 VS 2031
Figure 6. Heart Disease
Figure 7. Vascular Disease
Figure 8. Gene Therapy On Cardiovascular Disease Report Years Considered
Figure 9. Global Gene Therapy On Cardiovascular Disease Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 10. Global Gene Therapy On Cardiovascular Disease Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Region: 2020 VS 2024
Figure 12. North America Gene Therapy On Cardiovascular Disease Revenue (US$ Million) Growth Rate (2020-2031)
Figure 13. Europe Gene Therapy On Cardiovascular Disease Revenue (US$ Million) Growth Rate (2020-2031)
Figure 14. China Gene Therapy On Cardiovascular Disease Revenue (US$ Million) Growth Rate (2020-2031)
Figure 15. Japan Gene Therapy On Cardiovascular Disease Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Global Gene Therapy On Cardiovascular Disease Market Share by Players in 2024
Figure 17. Global Top Gene Therapy On Cardiovascular Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy On Cardiovascular Disease as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Gene Therapy On Cardiovascular Disease Revenue in 2024
Figure 19. North America Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
Figure 20. North America Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
Figure 21. Europe Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
Figure 22. Europe Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
Figure 23. China Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
Figure 24. China Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
Figure 25. Japan Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
Figure 26. Japan Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
Figure 27. Renovacor Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 28. Gene Biotherapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 29. AskBio Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 30. Human Stem Cells Institute Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 31. Novartis Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 32. Biogen Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 33. Gilead Sciences Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 34. Sarepta Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 35. Alnylam Pharmaceuticals Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 36. Amgen Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 37. Spark Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 38. Akcea Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 39. Sunway Biotech Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 40. SIBIONO Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 41. AnGes Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 42. Orchard Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed
Table 1. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Gene Therapy On Cardiovascular Disease Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Gene Therapy On Cardiovascular Disease Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Gene Therapy On Cardiovascular Disease Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Gene Therapy On Cardiovascular Disease Revenue Share by Region (2020-2025)
Table 6. Global Gene Therapy On Cardiovascular Disease Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Gene Therapy On Cardiovascular Disease Revenue Share Forecast by Region (2026-2031)
Table 8. Global Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2020-2025)
Table 10. Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2020-2025)
Table 15. Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Gene Therapy On Cardiovascular Disease Application
Table 18. Global Gene Therapy On Cardiovascular Disease Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Gene Therapy On Cardiovascular Disease Market Share by Players (2020-2025)
Table 20. Global Top Gene Therapy On Cardiovascular Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy On Cardiovascular Disease as of 2024)
Table 21. Ranking of Global Top Gene Therapy On Cardiovascular Disease Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Gene Therapy On Cardiovascular Disease Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Gene Therapy On Cardiovascular Disease, Headquarters and Area Served
Table 24. Global Key Players of Gene Therapy On Cardiovascular Disease, Product and Application
Table 25. Global Key Players of Gene Therapy On Cardiovascular Disease, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Gene Therapy On Cardiovascular Disease Revenue Market Share by Company (2020-2025)
Table 29. North America Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Gene Therapy On Cardiovascular Disease Revenue Market Share by Company (2020-2025)
Table 33. Europe Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025) & (US$ Million)
Table 35. China Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025) & (US$ Million)
Table 36. China Gene Therapy On Cardiovascular Disease Revenue Market Share by Company (2020-2025)
Table 37. China Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025) & (US$ Million)
Table 38. China Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025) & (US$ Million)
Table 39. Japan Gene Therapy On Cardiovascular Disease Revenue by Company (2020-2025) & (US$ Million)
Table 40. Japan Gene Therapy On Cardiovascular Disease Revenue Market Share by Company (2020-2025)
Table 41. Japan Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2025) & (US$ Million)
Table 42. Japan Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2025) & (US$ Million)
Table 43. Renovacor Company Details
Table 44. Renovacor Business Overview
Table 45. Renovacor Gene Therapy On Cardiovascular Disease Product
Table 46. Renovacor Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 47. Renovacor Recent Development
Table 48. Gene Biotherapeutics Company Details
Table 49. Gene Biotherapeutics Business Overview
Table 50. Gene Biotherapeutics Gene Therapy On Cardiovascular Disease Product
Table 51. Gene Biotherapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 52. Gene Biotherapeutics Recent Development
Table 53. AskBio Company Details
Table 54. AskBio Business Overview
Table 55. AskBio Gene Therapy On Cardiovascular Disease Product
Table 56. AskBio Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 57. AskBio Recent Development
Table 58. Human Stem Cells Institute Company Details
Table 59. Human Stem Cells Institute Business Overview
Table 60. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product
Table 61. Human Stem Cells Institute Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 62. Human Stem Cells Institute Recent Development
Table 63. Novartis Company Details
Table 64. Novartis Business Overview
Table 65. Novartis Gene Therapy On Cardiovascular Disease Product
Table 66. Novartis Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 67. Novartis Recent Development
Table 68. Biogen Company Details
Table 69. Biogen Business Overview
Table 70. Biogen Gene Therapy On Cardiovascular Disease Product
Table 71. Biogen Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 72. Biogen Recent Development
Table 73. Gilead Sciences Company Details
Table 74. Gilead Sciences Business Overview
Table 75. Gilead Sciences Gene Therapy On Cardiovascular Disease Product
Table 76. Gilead Sciences Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 77. Gilead Sciences Recent Development
Table 78. Sarepta Therapeutics Company Details
Table 79. Sarepta Therapeutics Business Overview
Table 80. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product
Table 81. Sarepta Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 82. Sarepta Therapeutics Recent Development
Table 83. Alnylam Pharmaceuticals Company Details
Table 84. Alnylam Pharmaceuticals Business Overview
Table 85. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product
Table 86. Alnylam Pharmaceuticals Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 87. Alnylam Pharmaceuticals Recent Development
Table 88. Amgen Company Details
Table 89. Amgen Business Overview
Table 90. Amgen Gene Therapy On Cardiovascular Disease Product
Table 91. Amgen Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 92. Amgen Recent Development
Table 93. Spark Therapeutics Company Details
Table 94. Spark Therapeutics Business Overview
Table 95. Spark Therapeutics Gene Therapy On Cardiovascular Disease Product
Table 96. Spark Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 97. Spark Therapeutics Recent Development
Table 98. Akcea Therapeutics Company Details
Table 99. Akcea Therapeutics Business Overview
Table 100. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product
Table 101. Akcea Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 102. Akcea Therapeutics Recent Development
Table 103. Sunway Biotech Company Details
Table 104. Sunway Biotech Business Overview
Table 105. Sunway Biotech Gene Therapy On Cardiovascular Disease Product
Table 106. Sunway Biotech Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 107. Sunway Biotech Recent Development
Table 108. SIBIONO Company Details
Table 109. SIBIONO Business Overview
Table 110. SIBIONO Gene Therapy On Cardiovascular Disease Product
Table 111. SIBIONO Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 112. SIBIONO Recent Development
Table 113. AnGes Company Details
Table 114. AnGes Business Overview
Table 115. AnGes Gene Therapy On Cardiovascular Disease Product
Table 116. AnGes Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 117. AnGes Recent Development
Table 118. Orchard Therapeutics Company Details
Table 119. Orchard Therapeutics Business Overview
Table 120. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product
Table 121. Orchard Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025) & (US$ Million)
Table 122. Orchard Therapeutics Recent Development
Table 123. Gene Therapy On Cardiovascular Disease Market Trends
Table 124. Gene Therapy On Cardiovascular Disease Market Drivers
Table 125. Gene Therapy On Cardiovascular Disease Market Challenges
Table 126. Gene Therapy On Cardiovascular Disease Market Restraints
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of Figures
Figure 1. Gene Therapy On Cardiovascular Disease Product Picture
Figure 2. Global Gene Therapy On Cardiovascular Disease Market Share by Type: 2024 VS 2031
Figure 3. Viral Gene Therapy Features
Figure 4. Non-Viral Gene Therapy Features
Figure 5. Global Gene Therapy On Cardiovascular Disease Market Share by Application: 2024 VS 2031
Figure 6. Heart Disease
Figure 7. Vascular Disease
Figure 8. Gene Therapy On Cardiovascular Disease Report Years Considered
Figure 9. Global Gene Therapy On Cardiovascular Disease Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 10. Global Gene Therapy On Cardiovascular Disease Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Region: 2020 VS 2024
Figure 12. North America Gene Therapy On Cardiovascular Disease Revenue (US$ Million) Growth Rate (2020-2031)
Figure 13. Europe Gene Therapy On Cardiovascular Disease Revenue (US$ Million) Growth Rate (2020-2031)
Figure 14. China Gene Therapy On Cardiovascular Disease Revenue (US$ Million) Growth Rate (2020-2031)
Figure 15. Japan Gene Therapy On Cardiovascular Disease Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Global Gene Therapy On Cardiovascular Disease Market Share by Players in 2024
Figure 17. Global Top Gene Therapy On Cardiovascular Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy On Cardiovascular Disease as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Gene Therapy On Cardiovascular Disease Revenue in 2024
Figure 19. North America Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
Figure 20. North America Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
Figure 21. Europe Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
Figure 22. Europe Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
Figure 23. China Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
Figure 24. China Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
Figure 25. Japan Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2025)
Figure 26. Japan Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2025)
Figure 27. Renovacor Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 28. Gene Biotherapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 29. AskBio Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 30. Human Stem Cells Institute Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 31. Novartis Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 32. Biogen Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 33. Gilead Sciences Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 34. Sarepta Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 35. Alnylam Pharmaceuticals Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 36. Amgen Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 37. Spark Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 38. Akcea Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 39. Sunway Biotech Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 40. SIBIONO Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 41. AnGes Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 42. Orchard Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Tetrabenzyl Thiuram Disulfide Market Research Report 2025
Aug 04, 25
Global Diammonium Phosphate Fertilizer Market Research Report 2025
Aug 04, 25
Global Calcium Nitrate Fertilizer Market Research Report 2025
Aug 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232